Immuron Ltd — Capital/Financing Update 2019

Jul 16, 2019

==> picture [209 x 63] intentionally omitted <==

Underwritten public offer

Melbourne, Australia, July 17, 2019: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, as announced earlier today, the Company has entered into an underwritten public offer of 339,130 American Depositary Shares, or ADSs. Each ADS represents forty (40) ordinary shares of the Company with a public offering price of USD$4.00 per ADS that is fully underwritten.

The Company intends to issue the securities under its 10% capacity under Listing Rule 7.1A.

The offering is expected to close on July 19, 2019, subject to customary closing conditions. The estimated gross proceeds to the Company are expected to be approximately USD$1,356,520 prior to deducting underwriting discounts, commissions and other estimated offering expenses.

A fee of up to 6% is payable to the Underwriter.

-End-